News|Articles|July 1, 2016

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-07-06-2016
  • Volume 11
  • Issue 7

CordenPharma Expands Service Offerings

The company expanded its services to include oligonucleotide API development and manufacturing and received approval for its Caponago manufacturing facility.

On July 1, 2016, CordenPharma announced that it has expanded its services to include oligonucleotide API development and manufacturing. The investment was initiated by CordenPharma Colorado and is expected to be complete before the end of 2016, the company said in a press announcement. Corden’s portfolio for API and drug products includes peptides, lipids, and carbohydrates for API manufacturing and development. In late June, the Italian Medicines Agency approved Corden’s sterile injectable facility in Caponago, Italy. The manufacturing facility, which was recently completed, will support customer development and commercial programs by providing service in aseptic filling of liquid and lyophilized vials, and pre-filled syringes. This adds to the facility’s existing terminal sterilization capabilities.

Source: Corden Pharma


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.